AlTi Global Inc. Grows Holdings in Eli Lilly and Company $LLY

Key Points

• AlTi Global Inc. increased its stake in Eli Lilly and Company by 29.0%, owning 1,712 shares valued at approximately $1.34 million at the end of the 2nd quarter.
• Eli Lilly reported earnings of $6.31 per share, surpassing expectations and representing a 37.6% increase in revenue year-over-year.
• Insider trading activity included notable purchases by Director J Erik Fyrwald, who bought shares valued at over $1 million, reflecting confidence in the company’s performance.

AlTi Global Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 29.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,712 shares of the company's stock after purchasing an additional 385 shares during the quarter. AlTi Global Inc.'s holdings in Eli Lilly and Company were worth $1,342,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Cardinal Point Capital Management ULC raised its position in Eli Lilly and Company by 70.5% in the 2nd quarter. Cardinal Point Capital Management ULC now owns 711 shares of the company's stock valued at $554,000 after purchasing an additional 294 shares during the last quarter. Opes Wealth Management LLC raised its position in Eli Lilly and Company by 355.8% in the 2nd quarter. Opes Wealth Management LLC now owns 1,536 shares of the company's stock valued at $1,197,000 after purchasing an additional 1,199 shares during the last quarter. 180 Wealth Advisors LLC raised its position in Eli Lilly and Company by 4.9% in the 2nd quarter. 180 Wealth Advisors LLC now owns 2,763 shares of the company's stock valued at $2,153,000 after purchasing an additional 129 shares during the last quarter. Guardian Asset Advisors LLC raised its position in Eli Lilly and Company by 1.2% in the 2nd quarter. Guardian Asset Advisors LLC now owns 3,516 shares of the company's stock valued at $2,743,000 after purchasing an additional 43 shares during the last quarter. Finally, Carnegie Investment Counsel raised its position in Eli Lilly and Company by 34.0% in the 2nd quarter. Carnegie Investment Counsel now owns 12,572 shares of the company's stock valued at $9,800,000 after purchasing an additional 3,193 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.6%

Shares of Eli Lilly and Company stock opened at $825.86 on Friday. The firm has a fifty day moving average of $768.01 and a two-hundred day moving average of $768.14. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $781.65 billion, a P/E ratio of 53.98, a PEG ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Weiss Ratings reiterated a "hold (c+)" rating on shares of Eli Lilly and Company in a research report on Friday. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $938.61.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald purchased 1,565 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.